Viewing data from:

VINCRISTINE SULFATE

ANDA

VINCRISTINE SULFATE | A070411 | ABRAXIS PHARMACEUTICAL PRODUCTS

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Vincristine Sulfate (2023)

Total Spending

$7K

Total Claims

474

Beneficiaries

138

Avg Cost/Unit

$7.50

Spending Trend

$4K(2019)→$3K(2020)→$4K(2021)→$5K(2022)→$7K(2023)

YoY Change:+39.1%

5yr CAGR:+10.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs8 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

MINAKEM HIGH POTENTVINCRISTINE SULFATE

DMF 49321983

HUBEI HONCH PHARMACEUTICAL CO LTDVINCRISTINE SULFATE

DMF 399432024

GEDEON RICHTER LTDInactiveVINCRISTINE SULFATE

DMF 35071979

PLANTEX LTD CHEMICAL AND PHARMACEUTICAL WORKSInactiveVINCRISTINE SULFATE USP

DMF 48621983

CHEMWERTH INCInactiveVINCRISTINE SULFATE

DMF 62211986

SAPCOL INTERNATIONAL LTDInactiveVINCRISTINE

DMF 62901986

CIPLA LTDInactiveVINCRISTINE SULFATE USP

DMF 65001986

ADITHYA ALKALOIDS LTDInactiveVINCRISTINE SULFATE

DMF 112851995

HANA BIOSCIENCES INCInactiveVINCRISTINE SULFATE LIPOSOME INJECTION

DMF 126261997

GUANGZHOU HUANYE PHARMACEUTICAL CO LTDInactiveVINCRISTINE SULFATE USP (NON-STERILE BULK DRUG)

DMF 185792005

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 1MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Sep 10, 1986

No patent or exclusivity listings for this strength.